Damian Lamb
Founder bei Genesys Capital Partners, Inc.
Profil
Mr. Lamb is co-Founder and Managing Director of Genesys Capital.
With over 20 years experience in life sciences venture capital, he is one of Canada’s most experienced investors and company builders.
Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $300 million in venture capital funds, and has been involved in deploying over $250 million across 38 investments.
He currently serves on the Boards of Flosonics Medical and the Centre for Probe Development and Commercialization at McMaster University.
Mr. Lamb has served on the Board of Affinium Pharmaceuticals (acquired by Debiopharm), Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of Fusion Pharmaceuticals Inc., Profound Medical Corp.
and DELEX Therapeutics Inc. when it was sold to YM BioSciences (now Gilead).
Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.
Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp.
He is a frequently invited speaker at biotechnology industry conferences.
Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with a Master of Science in Molecular Neurobiology and also holds an MBA from Queen’s University.
Aktive Positionen von Damian Lamb
| Unternehmen | Position | Beginn |
|---|---|---|
Genesys Capital Partners, Inc.
 Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | Founder | 28.12.2010 |
Flosonics Medical
 Flosonics Medical Packaged SoftwareTechnology Services Flosonics Medical develops and operates medical software platform for the management of critically ill patients. The company was founded by Joe Eibl, Jon-Emile Kenny, Andrew Eibl, and Sachit Harish and is headquartered in Sudbury, Canada. | Director/Board Member | - |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Director/Board Member | - |
Ehemalige bekannte Positionen von Damian Lamb
| Unternehmen | Position | Ende |
|---|---|---|
| FUSN PHAR | Chairman | 02.11.2020 |
| PROFOUND MEDICAL CORP. | Chairman | 13.06.2019 |
Millenium Biologix Corp.
 Millenium Biologix Corp. BiotechnologyHealth Technology Millenium Biologix Corp. is focused on the development and commercialization of next generation, skeletal tissue regeneration products and implantable medical devices, initially targeted for orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Its core business activities are focused on tissue engineering products, and on orthobiologicals. It was founded on April 1, 1998 and is headquartered in Kingston, ON. | Director/Board Member | 08.05.2007 |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Private Equity Investor | 31.12.1999 |
The Health Technology Exchange
 The Health Technology Exchange Financial ConglomeratesFinance The Health Technology Exchange provides non-dilutive project financing to the medical and assistive technology sector. The company’s programs include Health Technology Commercialization Program (HTCP), REACH Innovation Procurement program and MedTech ecosystem support activities. Its initiatives include The Harmony Project, The HTX Soft Landing Program and Medtech RISE. The company was founded in 2004 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Ausbildung von Damian Lamb
| Queen's University of Belfast | Masters Business Admin |
| McMaster University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PROFOUND MEDICAL CORP. | Health Technology |
| FUSN PHAR | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Millenium Biologix Corp.
Millenium Biologix Corp. BiotechnologyHealth Technology Millenium Biologix Corp. is focused on the development and commercialization of next generation, skeletal tissue regeneration products and implantable medical devices, initially targeted for orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Its core business activities are focused on tissue engineering products, and on orthobiologicals. It was founded on April 1, 1998 and is headquartered in Kingston, ON. | Health Technology |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
Genesys Capital Partners, Inc.
Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | Finance |
DELEX Therapeutics, Inc.
 DELEX Therapeutics, Inc. BiotechnologyHealth Technology Part of Gilead Sciences, Inc., DELEX Therapeutics, Inc. is a Canadian company that researches and develops inhalation pain treatment products for cancer patients. The private company is based in Mississauga, Canada. DELEX Therapeutics was acquired by YM BioSciences, Inc. on May 03, 2005 for $7.60 million. | Health Technology |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
Ionalytics Corp.
 Ionalytics Corp. Industrial MachineryProducer Manufacturing Part of Thermo Fisher Scientific, Inc., Ionalytics Corp. designs and manufactures ion-filtering equipment and related engineering instruments. The private company is based in Ottawa, Canada. Ionalytics was acquired by Thermo Electron Corp. on August 11, 2005. | Producer Manufacturing |
Profound Medical, Inc.
 Profound Medical, Inc. Medical SpecialtiesHealth Technology Profound Medical, Inc. develops and commercializes a unique, minimally invasive treatment for prostate cancer. Its novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. The firm deliveres via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. Its method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The company was founded in June 2008 by Michael Bronskill, Rajiv Chopra and Paul Chipperton and is headquartered in Toronto, Canada. | Health Technology |
The Health Technology Exchange
The Health Technology Exchange Financial ConglomeratesFinance The Health Technology Exchange provides non-dilutive project financing to the medical and assistive technology sector. The company’s programs include Health Technology Commercialization Program (HTCP), REACH Innovation Procurement program and MedTech ecosystem support activities. Its initiatives include The Harmony Project, The HTX Soft Landing Program and Medtech RISE. The company was founded in 2004 and is headquartered in Toronto, Canada. | Finance |
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
Flosonics Medical
Flosonics Medical Packaged SoftwareTechnology Services Flosonics Medical develops and operates medical software platform for the management of critically ill patients. The company was founded by Joe Eibl, Jon-Emile Kenny, Andrew Eibl, and Sachit Harish and is headquartered in Sudbury, Canada. | Technology Services |
